

EXHIBIT B

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

GENENTECH, INC. ~~and CITY OF HOPE,~~₂

~~Plaintiffs~~ Plaintiff,

v.

AMGEN INC.,

Defendant.

C.A. No. 18-924-CFC

~~CONFIDENTIAL—FILED UNDER SEAL~~

JURY TRIAL DEMANDED

~~SECOND~~ THIRD AMENDED COMPLAINT

~~Plaintiffs~~ Plaintiff Genentech, Inc. (“Genentech”) ~~and City of Hope (collectively,~~
~~“Plaintiffs”)~~ ~~bring this Second~~ brings this Third Amended Complaint ~~for declaratory and injunctive~~
~~relief~~ against Defendant Amgen Inc. (“Amgen”) to address Amgen’s infringement of patents
relating to Genentech’s groundbreaking breast cancer drug Herceptin®.

NATURE OF THE CASE

1. Breast cancer is a serious disease affecting over 2.8 million women in the United States. Approximately 20-25% of those women suffer from “HER2-positive” breast cancer. This is a particularly aggressive form of the disease characterized by overexpression of human epidermal growth factor receptor 2 (i.e., “HER2”) proteins due to excessive HER2 gene amplification.

2. In the early 1990s, a diagnosis of HER2-positive breast cancer was effectively a death sentence: patients had an average life expectancy of only 18 months. The quality of life for those patients was markedly poor—the disease rapidly metastasized (*i.e.*, spread to other parts of the body). The only available treatments were invasive and disfiguring surgery and

chemotherapeutic drugs with harsh side effects, and those treatments added little to the patient's life span.

3. The treatment of HER2-positive breast cancer, and the lives of millions of women suffering from the disease, changed dramatically with Genentech's development of Herceptin[®]. Herceptin[®] was the first drug of its kind—an antibody called trastuzumab that specifically targeted the biological mechanism that makes HER2-positive breast cancer such an aggressive form of the disease.

4. Although the scientific community was initially skeptical that such an antibody-based therapy could work, Genentech's specific methods of using Herceptin[®] proved remarkably effective. Indeed, after Genentech revealed the results of its clinical studies, the scientific community hailed Herceptin[®] as “the beginning of a whole new wave of biological drugs that modulate the causes of cancer”¹ and a sign that “the whole field of cancer research has turned a corner.”²

5. Since FDA approval of Herceptin[®] in 1998, Genentech has worked diligently to develop new methods of using Herceptin[®]—including improved dosing schedules and broader indications—to expand access to therapy and improve the quality of life for millions of patients worldwide. This research has greatly expanded the number of patients who are able to benefit from Herceptin[®]. To further expand access to this lifesaving drug, Genentech also provides Herceptin[®] free of charge to patients who are uninsured or cannot afford treatment and assists

¹ Gina Kolata and Lawrence M. Fisher, *Drugs to Fight Breast Cancer Near Approval*, NEW YORK TIMES (FRONT PAGE) (Sept. 3, 1998).

² Robert Langreth, *Breast-Cancer Drug Is Backed by FDA Panel*, Wall Street J. (Sept. 3, 1998).

with out-of-pocket prescription-related expenses. All told, Genentech has spent over two decades, and billions of dollars, developing Herceptin[®] into the life-saving drug it is today.

6. Genentech's groundbreaking work developing Herceptin[®] was the result of years of research from a group of talented scientists. The United States Patent and Trademark Office recognized that innovative work by granting Genentech numerous patents claiming Herceptin[®], its manufacture, and its use. ~~And as one of the pioneers in the biotechnology field, Genentech collaborated with scientists at research institutions such as the City of Hope to make foundational inventions, such as efficient techniques for making antibodies that can be used as drugs.~~

7. Seeking to profit from the success of ~~Plaintiffs'~~Genentech's innovations, Amgen ~~is seeking~~sought FDA approval of a biosimilar version of Herceptin[®] called ABP 980. ~~ABP 980 is a copycat product for~~ (trastuzumab-anns). The FDA approved ABP 980, which Amgen ~~is seeking~~markets under the tradename Kanjinti, on June 13, 2019 for the same label indications and usage as Herceptin[®]. In fact, Amgen ~~is relying~~relied upon Genentech's own studies demonstrating the safety and efficacy of Herceptin[®] to obtain approval of its biosimilar product.

8. In 2010, Congress provided a pathway for resolving patent disputes relating to biosimilar products through the Biologics Price Competition and Innovation Act ("BPCIA"). Amgen initially purported to follow the process outlined in the BPCIA, which requires biosimilar applicants and innovator companies to exchange certain information concerning the biosimilar product and the patents that may be infringed by the manufacture and sale of the biosimilar product. *See* 42 U.S.C. § 262(I).

9. ~~Plaintiffs~~Genentech thus ~~bring~~brings this action for infringement pursuant to 35 U.S.C. § 271(e)(2) based upon Amgen's submission of its ~~aBLA~~Abbreviated Biologics License Application ("aBLA") for ABP 980. ~~Plaintiffs also seek~~Genentech also seeks a judgment of

infringement under 35 U.S.C. § 271(a), (b), and (g) that Amgen's manufacture, use, offer to sell, sale, or importation into the United States of Amgen's biosimilar product has infringed the patents described below. Genentech also seeks a declaratory judgment pursuant to 42 U.S.C. § 262(l)(9) and 28 U.S.C. § 2201 that the manufacture, use, offer to sell, sale, or importation into the United States of Amgen's biosimilar product would infringe the patents described below. Pursuant to 35 U.S.C. § 271(e)(4)(B), 42 U.S.C. § 262(l)(8)(B), 35 U.S.C. § 271(a), (b), (g), and/or 35 U.S.C. § 283, Plaintiffs Genentech also seek seeks a preliminary and/or permanent injunction barring Amgen's manufacture, use, offer to sell, sale, or importation of its biosimilar product prior to the expiration of those patents. ~~In the event that Amgen imports, manufactures, or launches its biosimilar product, and/or otherwise practices the patented inventions in the United States prior to the expiration of those patents, Plaintiffs also seek~~ Genentech also seeks monetary damages, including lost profits and/or a reasonable royalty, for Amgen's infringement of Genentech's patents, and any further relief as this Court may deem just and proper.

PARTIES

10. Plaintiff Genentech is a corporation organized and existing under the laws of the State of Delaware with its corporate headquarters at 1 DNA Way, South San Francisco, California 94080.

11. Genentech was founded in 1976 and for four decades has been at the forefront of innovation in the field of therapeutic biotechnology. Today, Genentech employs a large number of researchers, scientists, and post-doctoral staff members who routinely publish in top peer-reviewed journals and are among the leaders in total citations to their work by researchers.

Genentech currently markets numerous approved pharmaceutical and biologic drugs for a range

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.